The type of EGFR gene change may affect how lung cancer grows in the brain
Original title: Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE).
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at people already treated, so it shows a pattern but does not prove what works best.
The short version
In people whose lung cancer spread to the brain, the exact gene change they had was linked to how likely the brain tumors were to grow again.
What was studied. Doctors at 11 hospitals looked back at the records of 470 people with EGFR mutated non-small cell lung cancer that had spread to the brain. All had been treated with a drug called osimertinib, some with focused radiation to the brain as well. The records covered 2016 to 2024.
What they found. People had one of three kinds of EGFR gene change. Most had an exon 19 deletion (57%), some had L858R (33%), and a smaller group had atypical mutations (9.6%). After 24 months, the cancer in the brain had grown or spread again in 30% of the exon 19 deletion group, 47% of the L858R group, and 76% of the atypical group. People who got focused radiation early on had better outcomes in the brain, and the biggest benefit was in the atypical group.
What this means, and what it doesn't
What it could mean: Knowing which EGFR change you have may help your care team judge how closely to watch your brain. It may also help them decide whether to add focused radiation early instead of waiting. This is a question worth raising with your oncologist, since both the drug and the radiation are already in use.
What it doesn't mean: This is not a cure, and it is not a new treatment. The doctors looked back at records of people already treated. They did not run a trial that compared treatments head to head. That kind of study can show patterns, but it cannot prove that one choice caused the better result. It also does not mean everyone with an atypical mutation will have the cancer grow in the brain, or that everyone should get radiation early. Any decision still depends on your own situation and your care team.
Source: PubMed, July 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.